Journal of Medical Economics · 2019 · 15 citations · 23 references
PharmacyHealth Services AdministrationPharmacoeconomicsBudget Impact AnalysisCost-effectiveness AnalysisOutcomes ResearchBehavioral Intervention EvaluationBudget Impact ConsiderationsCost-effectiveness ModelingHealthcare Cost AnalysisMedicare FinancingObesity ManagementBudget Impact PerspectiveBudgetary CostingBudgetary Impact AssessmentCost Savings AnalysisObesity TreatmentPolicy Impact Modeling
Aims: To estimate the long-term budget impact of expanding Medicare coverage of anti-obesity interventions among adults aged 65 and older in the US.Materials and methods: This study analyzed a representative sample of Medicare beneficiaries from the combined 2008–2016 National Health and Nutrition Examination Surveys. Population characteristics, cost and effectiveness of anti-obesity interventions, and the sustainability of weight loss in real-life were modeled to project the budgetary impact on gross Medicare outlay over 10 years. Hypothetical scenarios of 50% and 67% increases in intervention participation above base case were used to model moderate and extensive Medicare coverage expansion of intensive behavior therapy and pharmacotherapy.Results: For each Medicare beneficiary receiving anti-obesity treatment, we estimate Medicare savings of $6,842 and $7,155 over 10 years under moderate and extensive coverage utilization assumptions, respectively. The average cost of intervention is $1,798 and $1,886 per treated participant. Taking the entire Medicare population (treated and untreated) into consideration, the estimated 10-year budget savings per beneficiary are $308 and $339 under moderate and extensive assumptions, respectively. Sensitivity analysis of drug adherence rate and weight-loss efficacy indicated a potential variation of budget savings within 7% and 22% of the base case, respectively. Most of the projected cost savings come from lower utilization of ambulatory services and prescription drugs.Limitations: Due to the scarcity of studies on the efficacy of pharmacotherapy among older adults with obesity, the simulated weight loss and long-term maintenance effects were derived from clinical trial outcomes, in which older adults were mostly excluded from participation. The model did not include potential side-effects from anti-obesity medications and associated costs.Conclusions: This analysis suggests that expanding coverage of anti-obesity interventions to eligible individuals could generate $20–$23 billion budgetary savings to Medicare over 10 years.
23
Trends in Obesity Among Adults in the United States, 2005 to 2014
Katherine M. Flegal, Deanna Kruszon‐Moran, Margaret D. Carroll et al. · JAMA · 2016 · 2.8K citations · Full text
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Jarl Torgerson, Jonathan Hauptman, Mark Boldrin et al. · Diabetes Care · 2004 · 1.9K citations · Full text
The Medicare Payment Advisory Commission.
Curreri Pw · PubMed · 1998 · 1.2K citations
Public Affairs, Health Policy, Health Services Administration +12
Weight Loss, Exercise, or Both and Physical Function in Obese Older Adults
Dennis T. Villareal, Suresh Chode, Nehu Parimi et al. · New England Journal of Medicine · 2011 · 1.1K citations · Full text